NCT06863870Active, not recruiting
Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma
Source: ClinicalTrials.gov · Last updated 7 Mar 2025
Brief summary (registry, in English)
the study aims to implement new approaches for the identification of circulating tumor cells and circulating microRNAs, which aim to silence the expression of genes and thus prevent the production of proteins in patients with advanced melanoma (uval, mucosal, of unknown origin). It also aims to verify whether their expression can be related to the prognosis of the disease and the response to treatments.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 35 (estimated)
- First submitted
- 10 Jan 2025
- Start date
- 24 May 2023
- Primary completion date
- 30 Sept 2024
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Diseases
- Melanoma
- NCT number
- NCT06863870
What you commit to
- Study type: Observational
- Planned participants: 35
- From 24 May 2023 to the primary completion date, 30 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Personal medical history of concomitant other cancer
Who the study is looking for
- Diagnosis of UM, MM or MUP
- Diagnosis of metastatic disease
- Age ≥ 18 years, at the time of the tissue collection
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Azienda Ospedaliero-Universitaria di Bologna Coordinator of this site? Confirm its status | Bologna | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.